356 related articles for article (PubMed ID: 19545565)
1. Host peroxisomal properties are not restored to normal after treatment of visceral leishmaniasis with sodium antimony gluconate.
Gupta S; Raychaudhury B; Datta SC
Exp Parasitol; 2009 Oct; 123(2):140-5. PubMed ID: 19545565
[TBL] [Abstract][Full Text] [Related]
2. Peroxisomal function is altered during leishmania infection.
Raychaudhury B; Banerjee S; Datta SC
Med Sci Monit; 2003 Apr; 9(4):BR125-9. PubMed ID: 12709663
[TBL] [Abstract][Full Text] [Related]
3. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
5. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
6. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
[TBL] [Abstract][Full Text] [Related]
7. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
8. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
9. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication.
Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM
Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981
[TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
11. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
[TBL] [Abstract][Full Text] [Related]
12. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
[No Abstract] [Full Text] [Related]
13. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters.
Sharma P; Singh N; Garg R; Haq W; Dube A
Peptides; 2004 Nov; 25(11):1873-81. PubMed ID: 15501518
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani: effect of therapy on expression of CD2 antigen and secretion of macrophage migration inhibition factor by T-cells in patients with visceral leishmaniasis.
Bimal S; Singh SK; Das VN; Sinha PK; Gupta AK; Bhattacharya SK; Das P
Exp Parasitol; 2005 Oct; 111(2):130-2. PubMed ID: 16023642
[TBL] [Abstract][Full Text] [Related]
17. Studies on stibanate resistant Leishmania donovani isolates of Indian origin.
Pal S; Mandal A; Duttagupta S
Indian J Exp Biol; 2001 Mar; 39(3):249-54. PubMed ID: 11495284
[TBL] [Abstract][Full Text] [Related]
18. Post kala-azar dermal leishmaniasis: the Kenyan experience.
Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR
East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521
[TBL] [Abstract][Full Text] [Related]
19. Verrucous papillomatous lesion of post-kala-azar dermal leishmaniasis: fine needle aspiration diagnosis of an unusual presentation.
Bhadani PP; Sen R; Singh RK
Acta Cytol; 2007; 51(2):252-4. PubMed ID: 17425218
[No Abstract] [Full Text] [Related]
20. Ketoconazole in antimonial unresponsive cases of Kala-azar.
Jha TK; Singh NK; Jha S
J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
